Frontiers in Cancer Research for the Elderly: Hearings Before the Select Committee on Aging, House of Representatives, Ninety-sixth Congress, First Session, June 19, 20, and 21, 1979
U.S. Government Printing Office, 1979 - Cancer - 536 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
activity addition agents American appear approach associated biological blood bone breast cancer cancer treatment carcinoma cause cells centers Chairman PEPPER chemotherapy clinical trials combination Committee complete cost cure death determine DEVITA disease doses drugs early effect effort elderly evaluation fact factors Figure funds given going hope hospital human immune important improved increased infection initial interferon involved less leukemia levels lives lung cancer major malignant material metastatic methods million months National Cancer Institute natural nodes normal observed occur Oncology patients percent possible prepared present problem production progress prostate question radiation received recent reference reported response risk significant stage statement studies surgery surgical survival Table Thank therapy tion treated treatment tumor United women
Page 171 - The University of Texas System Cancer Center — MD Anderson Hospital and Tumor Institute, Houston, Texas.
Page 16 - It was once said that the moral test of government is how that government treats those who are in the dawn of life, the children; those who are in the twilight of life, the elderly; and those who are in the shadows of life— the sick, the needy and the handicapped.
Page 286 - L-Phenylalanine mustard (LPAM) in the management of primary breast cancer: a report of early findings.
Page 276 - NCI in the late 1940' s and early 1950" s. The clinical development of the drug has been supported entirely by NCI in the US and partially in Europe through work done by the European Organization for the Research and Treatment of Cancer and the Swiss Cancer Study Group. The drug has been supplied free to NCI, but clinical trial costs thus far are in the range of $250,000. References Lung Cancer 1. Eagan: Cancer Treat. Rep. 60:949, 1976. 2. Cavalli: Cancer Treat. Rep. 62:473. 1978.
Page 372 - I am a professor of medicine at the University of Texas Cancer Center, MD Anderson Hospital and Tumor Institute, Houston, Texas.
Page 487 - Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.
Page 511 - A: Predicting hormone responsiveness in human breast cancer, in McGuire WL, Carbone PP, Vollmer EP (eds) : Estrogen Receptors in Human Breast Cancer. New York, Raven Press, 1975, pp 17-30.
Page 286 - Combination chemotherapy as an adjuvant treatment in operable breast cancer.
Page 372 - Over the last 15 years, a tremendous amount of biological and chemical knowledge on interferon has been described in the scientific literature. Interferon has been shown to have potent antitumor effects in a variety of animal tumor models. Since interferon works primarily in the species of origin, we must use interferon from human sources in order to treat human disease. There are at least three primary types of interferon in the body.
Page 113 - Gone With The Wind,' it seems every new movie has either "hell" or "damn" in it. "I read the other day where some scientist thinks it's possible to put a man on the moon by the end of the century. They even have some fellows they call astronauts preparing for it down in Texas.